Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay

Biologicals

Volumn 26, Issue 2, 1998, Pages 155-166

  Ramasamy, Indra ^a   Farrugia, Albert ^a   Tran, Em ^a   Anastasius, Vincent ^a   Charnock, Alison ^a  

^a THERAPEUTIC GOODS ADMINISTRATION   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; COLLAGEN; POLYMER; VON WILLEBRAND FACTOR;

ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG PURIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; ION EXCHANGE CHROMATOGRAPHY; PRECIPITATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VON WILLEBRAND DISEASE;

EID: 0031757485     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1998.0127     Document Type: Article

References (28)

1. Cash JD, Gader AMA, Da Costa J. The release of plasminogen activator and factor VIII by LVP, AVP, DDAVP, ATIII and OT in man. Br J Harmatol 1974; 27: 363-364.
2. Mannucci PM, Aberg M, Nilsson IM et al. Mechanism of plasminogen activator and factor vIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93.
3. Lethagen S. Pathogenesis, clinical picture and treatment of von Willebrand's disease. Ann Med 1993; 27: 642-651.
4. Foster PA. A perspective on the use of Favtor VIII concentrates and cryoprecipitate prophylactically in surgery or therapeutic ally in severe bleeds in patients with von Willebrand's disease, unresponsive to DDAVP: results of an international study. Thromb Haemost 1995; 74: 1370-1378.
5. Scharrer I, Vigh T, Augoren-Pursun E. Experience with Haemate P in von Willebrand's disease in adults. Haemostasis 1994; 24: 298-303.
6. Pasi KJ, Williams MD, Enayat MS et al. Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat treated Factor VIII concentrate (BPL 8Y). Br J Haematol 1990; 75: 228-233.
7. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140-1143.
8. Raines G, Aumann H, Sykes et al. Multimeric analysis of von Willebrand factor by molecular sieving electrophoresis in sodium dodecyl sulphate agarose gel. Thromb Res 1990; 60: 201-212.
9. Zuzel M, Nilsson IM, Aaberg M. A method for measuring plasma ristocetin cofactor activity. Thromb Res 1978; 12: 745-754.
10. Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-311.
11. Favoloro EJ, Grispo L, Dinale A et al. Von Willebrand's disease: laboratory investigation using an improved functional assay for von Willebrand factor. Pathology 1993; 25: 152-158.
12. Santoro SA. Preferential binding of high molecular weight forms of von Willebrand factor to fibrillar collagen. Biochem Biophys Acta 1983; 756: 123-126.
13. Favoloro EJ, Facey D, Grispo L. Laboratory assessment of von Willebrand factor. Coag Trans Med 1995; 104: 264-271.
14. Human Coagulation facteur VIII, freeze dried. European Pharmacopoeia Commission Guideline. PA/PH/Exp. 3T(96) 180.
15. Fricke WA, Lamb MA, Rastogi SC. Standards for assay of von Willebrand factor concentrates: A collaborative study. Thromb Haem 1993; 70: 351-356.
16. Scott DM, Griffin B, Pepper DS et al. The binding of purified factor VIII/von Willebrand factor to collagens of differing type and form. Thromb Res 1981; 24: 467-472.
17. Cumming AM, Fildes S, Cumming IR et al. Clinical and laboratory evaluation of National Health Service factor VIII concentrate (8Y) for the treatment of von Willebrand's disease. Br J Haematol 1990; 75: 234-239.
18. Mazurier C, Jorieux S, de Romeuf C et al. In vitro evaluation of a very high purity solvent/detergent treated von Willebrand factor concentrate. Vox Sang 1991; 61: 1-7.
19. Goudemand J, Mazurier C, Marey et al. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity. Br J Haematol 1992; 80: 214-221.
20. Winkelman L, Owen NE, Evans R et al. Severely heated therapeutic factor VIII concentrate of high specific activity. Vox Sang 1989; 59: 97-103.
21. Burnouf T, Bourouf-Radosevich M, Huart JJ et al. A highly purified factor VIII:C concentrate prepared from cryoprecipitate by ion exchange chromatography. Vox Sang 1991; 60: 8-15.
22. Burnouf-Radosevich M, Burnouf T. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate. Vox Sang 1992; 62: 1-11.
23. Favoloro EJ, Grispo L, Exner T et al. Development of a simple collagen based ELISA assay aids in the diagnosis of and permits sensitive discrimination between type I and type II, von Willebrand's disease. Blood Coagulation and Fibrinolysis 1991; 2: 285-291.
24. Addiego JE, Gomperts E, Shu Len Liu et al. Treatment of haemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIII C immunoaffinity chromatography. Thromb Haemos 1992; 67: 19-27.
25. Mannucci M, Tenconi PM, Castaman G et al. Comparison of four virus inactivated plasma concentrates for the treatment of severe von Willebrand disease: a cross over randomised trial. Blood 79: 3130-3137.
26. Federic AB, Bader R, Pagani S et al. Binding of von Willebrand factor to glycoprotein Ib and IIb/IIIa complex: affinity is related to multimeric size. Br J Haematol 1986; 73: 93-99.
27. Furlan M, Robles R, Lammle B. Partial purification and characterisation of a protease from human plasma cleaving von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA 1993; 90: 7503-7507.
28. Mannucci PM, Moia M, Rebulla P et al. Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Haematol 1987; 25: 55-65.